Monahan Joseph's most recent trade in Aclaris Therapeutics Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 50,000 | 281,995 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 50,000 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.99 per share. | 01 Mar 2025 | 27,258 | 265,662 (0%) | 0% | 2.0 | 54,243 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 10,925 | 292,920 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 10,925 | 10,925 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 293,500 | 293,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 83,900 | 83,900 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 243,312 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 11,317 | 231,995 (0%) | 0% | 2.5 | 28,066 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 228,562 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 15,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 73,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 245,533 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 52,667 | 52,667 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Dec 2024 | 32,937 | 212,596 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 17,380 | 35,287 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 17,380 | 229,976 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Dec 2024 | 8,914 | 221,062 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Dec 2024 | 15,000 | 171,783 (0%) | 0% | 0 | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 184,641 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 14,569 | 170,072 (0%) | 0% | 1.2 | 18,066 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 12,500 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 12,500 | 190,314 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 10,925 | 21,850 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 10,925 | 180,997 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 3,531 | 186,783 (0%) | 0% | 1.2 | 4,378 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 01 Mar 2024 | 3,183 | 177,814 (0%) | 0% | 1.2 | 3,947 | Common Stock |
| Aclaris Therapeutics Inc | Monahan Joseph | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 206,500 | 206,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 147,500 | 147,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Monahan Joseph | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 137,224 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 22,500 | - | - | Restricted Stock Unit | |
| Aclaris Therapeutics Inc | Monahan Joseph | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 2,583 | 134,641 (0%) | 0% | 1.2 | 3,100 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 7.32 per share. | 21 Aug 2023 | 6,000 | 135,724 (0%) | 0% | 7.3 | 43,895 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.28 per share. | 20 Jun 2023 | 6,000 | 141,724 (0%) | 0% | 10.3 | 61,663 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 50,000 | 100,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 50,000 | 155,136 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.63 per share. | 01 Mar 2023 | 16,037 | 147,724 (0%) | 0% | 12.6 | 202,615 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.37 per share. | 01 Mar 2023 | 14,800 | 151,261 (0%) | 0% | 12.4 | 183,024 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 13,750 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 13,750 | 105,136 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 12,500 | 163,761 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 12,500 | 12,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 10,925 | 32,775 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 10,925 | 166,061 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 13.06 per share. | 15 Feb 2023 | 5,000 | 91,386 (0%) | 0% | 13.1 | 65,311 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.98 per share. | 17 Oct 2022 | 5,000 | 101,386 (0%) | 0% | 16.0 | 79,908 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.28 per share. | 18 Apr 2022 | 30,000 | 106,386 (0%) | 0% | 16.3 | 488,298 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.71 per share. | 10 Mar 2022 | 27,165 | 136,386 (0%) | 0% | 15.7 | 426,803 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 153,100 | 153,100 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 151,051 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 150,000 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 43,700 | 43,700 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 13,750 | 101,051 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 13,750 | 13,750 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 12,500 | 25,000 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 12,500 | 163,551 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 1,050 | 87,684 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 1,050 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,333 | 87,675 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 2,333 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.22 per share. | 01 Sep 2021 | 1,041 | 86,634 (0%) | 0% | 17.2 | 17,926 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 50,000 | 107,132 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 50,000 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 01 Jun 2021 | 18,240 | 88,892 (0%) | 0% | 21.5 | 392,231 | Common Stock |
| Aclaris Therapeutics Inc | Joseph Monahan | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.31 per share. | 01 Jun 2021 | 3,550 | 85,342 (0%) | 0% | 22.3 | 79,205 | Common Stock |